Australia Inflammatory Bowel Disease Treatment Market Size & Outlook

The inflammatory bowel disease treatment market in Australia is expected to reach a projected revenue of US$ 468.0 million by 2030. A compound annual growth rate of 6.8% is expected of Australia inflammatory bowel disease treatment market from 2024 to 2030.
Revenue, 2023 (US$M)
$294.7
Forecast, 2030 (US$M)
$468.0
CAGR, 2024 - 2030
6.8%
Report Coverage
Australia

Australia inflammatory bowel disease treatment market, 2018-2030 (US$M)

Australia

Related Markets

Australia inflammatory bowel disease treatment market highlights

  • The Australia inflammatory bowel disease treatment market generated a revenue of USD 294.7 million in 2023 and is expected to reach USD 468.0 million by 2030.
  • The Australia market is expected to grow at a CAGR of 6.8% from 2024 to 2030.
  • In terms of segment, crohn's disease was the largest revenue generating type in 2023.
  • Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.


Inflammatory bowel disease treatment market data book summary

Market revenue in 2023USD 294.7 million
Market revenue in 2030USD 468.0 million
Growth rate6.8% (CAGR from 2023 to 2030)
Largest segmentCrohn's disease
Fastest growing segmentUlcerative Colitis
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCrohn's Disease, Ulcerative Colitis
Key market players worldwideAbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare


Other key industry trends

  • In terms of revenue, Australia accounted for 1.4% of the global inflammatory bowel disease treatment market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, Japan inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
  • Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 468.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Inflammatory Bowel Disease Treatment Market Scope

Inflammatory bowel disease treatment market segmentation & scope
Crohn's Disease
Ulcerative Colitis
Aminosalicylates
Corticosteroids
TNF Inhibitors
IL Inhibitors
Anti-integrin
JAK Inhibitors
Other Drug Class
Oral
Injectable
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Inflammatory Bowel Disease Treatment Market Companies

Name Profile # Employees HQ Website

Australia inflammatory bowel disease treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.


Crohn's disease was the largest segment with a revenue share of 58.13% in 2023. Horizon Databook has segmented the Australia inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.


In July 2021, Xeljanz was made available in the Pharmaceutical Benefits Scheme to enhance the treatment availability to Australian IBD patients. This step was taken to provide care for the increasing burden of patients that required innovative medications.

This further depicts the government’s support for innovative drugs with high efficacy. In January 2022, Australia announced starting of a 4-year partnership for research between Hudson Institute and Biome Bank on microbiome medicine for inflammatory bowel disease patient treatment.

The research further aims to target pediatric patients in the country for reducing the disease burden. The unmet need for access to specialists is a major factor influencing the rising IBD prevalence in the country. The development of programs to increase access to gastroenterologists is projected to propel drug adoption.

Reasons to subscribe to Australia inflammatory bowel disease treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Australia inflammatory bowel disease treatment market databook

  • Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Australia inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Australia inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Australia inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)

Australia Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)

Australia inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more